Foresee Pharmaceuticals Co., Ltd. (TPEX:6576)

Market Cap	12.45B +24.8%
Revenue (ttm)	431.27M +3.0%
Net Income	-883.15M
EPS	-5.70
Shares Out	157.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,873
Average Volume	196,611
Open	82.60
Previous Close	79.70
Day's Range	78.70 - 82.60
52-Week Range	61.60 - 93.70
Beta	0.67
RSI	48.14
Earnings Date	May 12, 2026

About Foresee Pharmaceuticals

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6576

Financial Performance

In 2025, Foresee Pharmaceuticals's revenue was 431.27 million, an increase of 3.01% compared to the previous year's 418.69 million. Losses were -883.15 million, -18.31% less than in 2024.